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Interactions between herbs and drugs may increase or decrease the pharmacological or toxicological 
effects of either component. Experimental data on the pharmacokinetic interactions between herbal 
products and drugs are limited. This study attempted to investigate the effect of Bacopa monnieri Linn. 
(Brahmi) formulation on the pharmacokinetics of amitriptyline in rats. In this study, rats were randomly 
divided into two groups (n = 6 each) which were served as a control (amitriptyline alone) and treatment 
group (amitriptyline with B. monnieri), respectively. Rats in the treatment group received B. monnieri 
(31 mg/kg/day) whereas the control group received normal saline by oral gavage for seven days before 
a single intragastric administration of 25 mg/kg amitriptyline. Plasma concentrations of amitriptyline 
were measured up to 24 h after its administration by a developed and validated high-performance liquid 
chromatography method. Pretreatment with B. monnieri produced a significant increase in the maximum 
plasma concentration (Cmax), area under the curve (AUC0-t) and elimination half-life (t1/2) of amitriptyline 
by 16.8%, 26.5%, and 15.5%, respectively, compared to amitriptyline alone. Moreover, oral clearance 
and volume of distribution (Vss) were decreased by 26.2% and 15.5% respectively. This study concluded 
that B.monnieri significantly enhanced the oral bioavailability of amitriptyline in rats. 
Keywords: Herbal drug interaction. Bacopa monnieri/effects. Amitriptyline/pharmacokinetics. CYP450. 
Bioavailability.
INTRODUCTION
Amitriptyline, a tricyclic compound, has been 
widely used globally for decades in the treatment of 
mental illnesses, especially depression. It still serves as 
one of the most commonly used antidepressants. (Leucht, 
Huhn, Leucht, 2012). Although the mode of action of 
amitriptyline is not evident, it is speculated to act by 
inhibiting the reuptake of serotonin–norepinephrine at the 
adrenergic nerve endings, thus disrupting the functions of 
these chemicals (Tatsumi et al., 1997; Amin Bano, 2014). 
Amitriptyline is completely but slowly absorbed from 
the gastrointestinal tract after its oral uptake such that 
the peak plasma concentrations are achieved within 4 to 
8 h of its administration. It has a systemic bioavailability 
ranging from 33 to 62% and is subjected to extensive 
hepatic pre-systemic elimination (Schulz et al., 1983). 
Within the liver, the drug is primarily metabolized by the 
action of cytochrome P450 enzymes, namely, CYP2D6, 
CYP3A4, and CYP2C19 (Rudorfer, Potter, 1999). The 
significant adverse effects associated with therapeutic 
concentrations of amitriptyline are manifested in terms of 
a moderate therapeutic index; an overdose of it may prove 
to be dangerous.
Bacopa monnieri, a perennial herb, belongs to the 
family, Scrophulariaceae and is commonly known as 
Brahmi in the Ayurvedic system of medicine. It has been 
widely employed as a brain stimulator, antidepressant, and 
memory enhancer (Stough et al., 2001). Various research 
studies, performed using the standardized extracts of B. 
monnieri, have demonstrated the herb to facilitate the 
processes of acquisition, retention, and retrieval of learned 
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tasks. A study that evaluated the antidepressant potential of 
B. monnieri reported it exhibit a significant antidepressant 
activity in the most commonly used behavior paradigms 
in animal models of depression. These included forced 
swim test and learned helplessness test (Sairam et al., 
2002). Another study that employed different convulsive 
models in albino rats to investigate the anticonvulsant 
activity of an alcoholic extract of B. monnieri reported 
the presence of a broad spectrum of anticonvulsant 
profile of the extract in chemical, electrical, and hypoxic 
convulsions (Kaushik et al., 2009). Moreover, a clinical 
trial conducted to assess the effects of administration of 
B. monnieri (300 mg/day) over a period of 12 weeks on 
memory performance reported the ability of the herb 
to significantly improve the memory acquisition and 
retention in individuals over the age of 55 years (Morgan, 
Stevens, 2010). Another study that analyzed the effects 
of a standardized B. monnieri (300 mg/day) on cognitive 
performance, anxiety, and depression in the elderly 
individuals concluded it to be a plant with a potential 
to safely enhance the cognitive performance in aging 
(Calabrese et al., 2008). This hypothesis was also favored 
by the studies conducted in rodents where B. monnieri 
provided protection against age-related oxidative stress 
and some inflammatory conditions (Williams et al., 2014). 
It is also known to enhance the lifespan during stress 
conditions (Phulara et al., 2015). The above-mentioned 
findings have been strengthened by several clinical studies 
(Stough et al., 2001; Roodenrys, 2002; Calabrese et al., 
2008) that ascribed the observed antidepressant effects 
to its phytochemical constituents, known as bacoside. 
Bacoside is a mixture of four triglycosidic saponins, 
namely, bacoside A3, bacopaside II, bacopaside X, and 
bacopasaponin C (Singh et al., 1988; Dhawan, Singh, 
1996; Russo, Borrelli, 2005).
B. monnieri has an extensive market both in India 
and outside. The neuropharmacological properties of B. 
monnieri (Russo, Borrelli, 2005; Calabrese et al., 2008) 
considerably increase the chances of chronic or recurrent 
usage of the herb and its associated products by patients 
with mental illnesses. The prescription of therapeutic drugs 
to these patients significantly contributes to herb–drug 
interactions at the physiological levels. These interactions, 
in turn, may increase or decrease the pharmacological 
or toxicological effects of either component (Hu et al., 
2005). Inhibition or induction of hepatic and intestinal 
drug-metabolizing enzymes, particularly cytochrome 
P450 (CYP) and transporters (e.g., p-glycoprotein) act 
as the trigger for the interactions (Zhang et al., 2010a; 
Wanwimolruk, Prachayasittikul, 2014a; Wanwimolruk, 
Phopin, Prachayasittikul et al., 2014b). However, there 
exists a paucity of literature on the pharmacokinetic 
interactions between herbal products and drugs. The 
present study attempted to investigate the effects of a 
commercial formulation of B. monnieri (Brahmi) on 
the pharmacokinetics of amitriptyline using rodents as 
the model system. An extensive review of the literature 
revealed the presence of several analytical methods, based 
on high-performance liquid chromatography (HPLC), for 
the estimation of amitriptyline and some of its metabolites 
in biological samples (Ghahramani, Lennard, 1996; 
Aymard et al., 1997; Farag et al., 2013). However, the 
major drawbacks of these procedures are complexity, 
time constraint, and limited sensitivity, leading to the 
requirement of a rapid, specific, and sensitive analytical 
method. The present study aimed to develop a highly 
sensitive reversed-phase high-performance liquid 
chromatography (RP-HPLC-UV) method, followed by 
its validation for the quantification of amitriptyline in rat 
plasma.
MATERIAL AND METHODS
Material
Amitriptyline and imipramine, as internal standards 
(ISs), were purchased from Sigma-Aldrich (Germany). 
High-performance liquid chromatography (HPLC) 
grade LiChrosolv methanol and LiChrosolv acetonitrile 
were from Merck (Darmstadt, Germany). Chemicals of 
highest available commercial purity were utilized. The 
commercial formulation of B. monnieri (Himalaya Drug 
Company, Bangalore, India) was procured from the local 
market. The HPLC-grade solvents were used for HPLC 
determinations. Milli-Q plus water (Millipore, Bedford, 
MA, United States) was used for all preparations. All other 
chemicals were of analytical grade.
Animals and study design
The study was conducted in accordance with current 
legislation on animal experiments as per Institutional 
Animal Ethical Committee (CPCSEA Approval no. 962/
PO/Re/S/06/CPCSEA). Twelve male Wistar albino rats, 
weighing 225 to 250 g were provided by the animal house, 
Alwar Pharmacy College, Alwar, Rajasthan. The rats were 
housed under standard animal conditions with alternate 12 
h of light and dark cycles in an environment maintained 
at a constant temperature prior to the study. Water was 
supplied ad libitum. Rats were randomly divided into two 
groups (n = 6 each); one served as the control (amitriptyline 
alone), and the other group served as the treatment group 
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(amitriptyline with B. monnieri). A randomized parallel 
design study was employed to study the pharmacokinetics 
of amitriptyline. Rats in the control group were provided 
normal saline orally (10 mL/kg) for 7 consecutive days 
followed by administration of amitriptyline (25 mg/kg bw 
p.o.) on day 8, 1 h after administration of normal saline. 
Amitriptyline was administered as an aqueous solution in 
0.5% (w/v) sodium carboxy-methyl cellulose (CMC) at a 
dose of 25 mg/kg bw p.o. Rats in the treatment group were 
administered B. monnieri extract in 0.5% CMC at a dose 
of 31 mg/kg/day, p.o. in saline water (Singh et al., 2013) 
for 7 consecutive days. The rats were made to fast for at 
least 12 h (overnight) with free access to water before the 
day of the experiment. On the morning of day 8, the last 
dose of B. monnieri was administered to the fasting rats. 
One hour after the administration of the last dose of B. 
monnieri, amitriptyline aqueous solution in 0.5% (w/v) 
CMC (25 mg/kg p.o.) was administered to these rats. The 
drug was administered via gastric gavage throughout the 
study.
Blood collection
A total of 1 mL of blood samples were collected into 
heparinized vacutainer tubes from the retroorbital plexus 
of each rat using capillary tubes before and after the 
administration of amitriptyline at 0, 1, 2, 4, 6, 8, 12, and 
24 h. The blood samples were immediately centrifuged 
at 2,500×g for 10 min to separate the plasma that was 
stored at –80 ºC until analysis. To replace the fluid loss, 
equal volumes of normal saline were injected through the 
cannula in all experiments. The same sampling scheme 
was followed for rats in the treatment group to determine 
the plasma concentrations of amitriptyline and evaluate 
the effect of B. monnieri on amitriptyline disposition in 
rats.
Amitriptyline assay by HPLC Method
Instrumentations and chromatographic conditions
The high-performance liquid chromatography 
(Waters, 1525 Binary HPLC pump) employed was 
equipped with the Waters-2489 UV-visible detector 
and Waters-2707 Autosampler and operated by Breeze 
2 service pack A (SPA) software, Waters Corporation. 
The chromatographic identification was conducted at 
ambient temperature. The mobile phase consisted of 
a v/v ratio of acetonitrile and potassium dihydrogen 
phosphate buffer (KH2PO4, 38:62), which was delivered at 
the isocratic condition with a flow rate of 1 mL/min. EC 
150/4.6-NUCLEODUR Sphinx RP, 5 µm MACHERY-
NAGEL column was used to elute amitriptyline at a 
wavelength (lmax) of 254 nm. Different combinations 
of solvent systems of acetonitrile, buffer (KH2PO4): 
acetonitrile, and formic acid: water, and methanol: 
water: acetonitrile were tried to determine the optimum 
conditions for the separation and standardization of 
amitriptyline. The mobile phase consisted of acetonitrile 
and 70 mM KH2PO4 buffer. Its pH was adjusted to 4.5 
by 85% orthophosphoric acid in a ratio of 38:62 (v/v). 
The selection of mobile phase was based on its ability to 
provide high resolution for amitriptyline with minimal 
tailing.
Sample preparation
The samples for analysis were prepared by the 
protein precipitation method. Plasma samples stored at 
around − 80˚C were thawed at room temperature and 
vortexed for 30 s to ensure homogeneity. The internal 
standard (8 µL, 100 µg/mL) was added to 200 µL of 
plasma sample, and 592 µL of acetonitrile was added 
to precipitate the protein from the sample. The samples 
were mixed gently for 1.5 min followed by centrifugation 
at 12,000 rpm for 10 min. After centrifugation, 700 µL 
of clear supernatant was transferred into HPLC vials. 
Finally, 25 µL of each sample was subjected to HPLC-
UV analysis.
Calibration and control samples
The linearity of an analytical method refers to its 
ability to furnish test results that are directly proportional 
to the concentration of an analyte in the samples 
within a given range. In other words, linearity is the 
relationship between the concentration of analyte and 
assay measurement (ICH, 1996). We used correlation 
coefficient (R2) obtained from the linear regression to 
demonstrate the linearity of the relationship between the 
peak area ratio and the concentration. The experiment 
was performed in triplicates with the concentration of 
analyte ranging from 0.125 to 50.0 µg/mL. The relative 
standard deviations were calculated for all the calibration 
curve slopes. The observed straight-line equation, 
y = 0.0343 × − 0.0026 (R2 = 0.9994) was used for the 
calculation of plasma concentrations of amitriptyline.
Validation and stability of HPLC method
The guidelines of the international conference on 
harmonization were employed to validate the HPLC 
method in terms of linearity, specificity, sensitivity, 
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precision, and accuracy (ICH, 1996). The robustness of the 
method was evaluated by intentionally introducing minor 
modifications in the mobile phase volume ratios. These 
included mobile phase having different compositions of 
acetonitrile-70 mM KH2PO4 (6038:62 ± 5 mL), alteration 
of the pH of buffer (4.5 ± 0.2), and slight changes in the 
isocratic flow rate (1.0 ± 0.2 mL/min) of the mobile phase. 
All the validation parameters were studied in triplicate 
(n=3) at a concentration of 20 µg/mL. The stability of 
amitriptyline in plasma at 4 and 20 ºC and after freeze–
thaw cycles was determined.
Pharmacokinetic analysis
We utilized the non-compartmental analysis to 
determine the pharmacokinetic parameters of amitriptyline 
after oral administration. The maximum observed plasma 
concentration (Cmax) and the time to reach this concentration 
(Tmax) following oral administration were calculated from 
the observed data. The volume of distribution at steady 
state (Vss) was calculated as (AUMC0-inf/AUC0-inf)*CL 
and total body clearance (CL) as dose/AUC0-inf. The area 
under the plasma concentration versus time curve (AUC0-t) 
was calculated by the trapezoidal rule with extrapolation 
to infinity. The linear regression analysis of the terminal 
portion of the log concentration–time data was utilized to 
calculate the apparent terminal elimination rate constant 
(Kel or λz) of amitriptyline. Amitriptyline apparent terminal 
elimination half-life (t1/2) was calculated as (ln2)/λz, 
where λz is the elimination rate constant. Pharmacokinetic 
analysis was performed using the program, PKSolver for 
Microsoft Excel (Zhang et al., 2010b).
Statistical data analysis
All statistical data were expressed as the mean 
± standard deviation (SD). Student’s t-test on log-
transformed data was utilized for assessing the differences 
in the pharmacokinetic parameters of amitriptyline with 
and without B. monnieri. Data were considered statistically 
significant at a p<0.05. All calculations were performed 
using GraphPad Prism, version 3.00 for Windows (San 
Diego, CA, United States).
Herbal medicine and dose calculation
The recommended adult dose of B. monnieri extract 
containing 20% of total bacopasides was 300 to 400 mg 
daily. A dose equivalent to human dose was used as the 
animal dose of these herbs and was calculated using the 
following equation. 
The human dose was selected from authentic herbal 
textbook resources (Reagan-Shaw, Nihal, Ahmad, 2008). 
The rat dose was found to be 31 mg/kg/day (Singh et al., 
2013).
RESULTS AND DISCUSSION
HPLC method development and validation for 
amitriptyline assay
The mobile phase of HPLC column was selected 
on the basis of previously used and described methods 
available for amitriptyline (Shen et al., 2010; Farag 
et al., 2013). The KH2PO4 buffer was checked at 
different concentrations (0.02, 0.05, and 0.07 M) for 
determining its efficient working concentration. At lower 
concentrations, amitriptyline and IS did not result in the 
same retention time. At a buffer concentration of 0.07 
M, the analytes were found to be well separated from 
plasma and hence it was chosen as the optimal buffer 
concentration. A range of buffer pH (3.0–7.0) was assayed 
to optimize the chromatographic separation. Optimal 
peak separation for amitriptyline and IS was produced 
using a pH value ranging between 3.0 and 7.0. However, 
when the spiked matrix samples were analyzed, the peaks 
from some of the plasma impurities matched with that 
of IS. A pH value of 4.5 was found to be optimal for the 
complete separation of amitriptyline and imipramine 
(IS); at this pH value, peaks were resolved well. The final 
mobile phase consisted of acetonitrile-KH2PO4 (0.07 M), 
pH 4.5 with 1.0 mL/min flow rate. This condition was 
found to be outstanding in terms of sensitivity and peak 
separation. The wavelengths checked in the present study 
were 230, 240, and 254 nm (Olsen, Sullivan, 1995). The 
wavelength of 254 nm was found to be optimal in terms 
of sensitivity for all the analytes; it also avoided the 
occurrence of numerous matrix impurities and exogenous 
substances.
Selectivity and specificity
The selectivity of any analytical method refers 
to the ability of the method to assess the analyte 
unequivocally in the presence of endogenous matrix 
compounds (i.e., plasma and proteins in this method). 
The chromatograms of plasma samples by using HPLC 
method are depicted in Figure 1. The symmetrical 
peaks were observed for amitriptyline with a retention 
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time of 6.15 min. There was no interference with the 
amitriptyline peak, and the overall chromatographic run 
time was 10 min. HPLC chromatograms of blank plasma 
(Figure 1A), plasma spiked with imipramine as IS 25 ng/
mL (Figure 1B), plasma sample spiked with amitriptyline 
(20 µg/mL) with retention times of 6.15 min. Retention 
time of the IS was 4.52 min (Figure 1C). The plasma 
samples obtained from rat, administered with 25 mg/kg 
p.o. dose of amitriptyline (Figure 1D), were compared 
to show the selectivity of the adopted HPLC method. 
The retention times of amitriptyline and imipramine 
were approximately 6.15 and 4.52 min, respectively. The 
designed HPLC method was found to be considerably 
selective, reflected by the absence of the appearance of 
any other interfering peaks around the retention times due 
to endogenous matrix substances or metabolite effects 
during quantification of amitriptyline and imipramine 
(IS) in plasma samples.
FIGURE 1 - HPLC chromatogram of blank plasma (A), plasma spiked with imipramine as internal standard (I.S) (B), plasma 
sample spiked with amitriptyline (20 µg/mL concentration) (Rt 6.15 min) and IS (Rt 4.5 min) (C), plasma samples obtained from 
rat, administered with 25 mg/kg, p.o. dose of amitriptyline (D).
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Precision and accuracy of developed HPLC 
method
An evaluation of the concentrations of three 
levels, namely, LLOQ, MQC, and ULOQ indicated 
the relative standard deviation (% RSD) values to be 
satisfactory. The calculated percentage recovery of 
the MQC level was found to be 100.14 ± 0.15%. The 
recovery values obtained from the analysis of different 
known concentrations by the developed HPLC method 
ranged from 98.31 to 99.02, indicating the method to be 
highly accurate. The percentage recovery determined for 
the lowest concentration (LLOQ) and MQC were 98.31 
± 0.85 and 99.23 ± 0.15%, respectively, and that of the 
highest concentration (ULOQ) was 99.02 ± 0.54 % during 
the inter-day analysis of the samples. All the results are 
listed in Table I. The reproducibility and reliability of the 
method was evident by low values of % RSD for LLOQ, 
MQC, and ULOQ.
Sensitivity, Limit of Detection (LOD), and Limit of 
Quantification (LOQ)
The lower limit of quantitation (LLOQ) was defined 
as the concentration of the lowest non-zero calibration 
standard, which met the acceptance criteria for accuracy 
and precision. The signal-to-noise ratios of 3.3:1 and 10:1 
were considered as LOD and LOQ, respectively, and were 
found to be 0.04334 and 0.13134 µg/mL, respectively.
Stability
Studies on the stability of the drug were performed 
to ensure reproducibility and reliability of the method. 
The amitriptyline stock solutions and its working stock 
solutions were stable at 4 °C for 3 months. The stability of 
the analyte in rat plasma was investigated under different 
storage conditions. It was found to be stable under the 
following conditions: at 10 °C for 24 h post-extraction, 
after three freeze and thaw cycles (from −20 to 25 °C) and 
at –80 °C for 90 days. The results of stability studies are 
summarized in Table II.
Recovery and matrix effects
The vortexing and ultracentrifugation were used for 
the extraction of the analyte and the IS. The percentage 
extraction recoveries of amitriptyline were found to be 
65.25, 76.75, and 74.28% in the low (LQC), medium 
(MQC), and high (HQC) concentration quality control 
samples (n=6), respectively. The percentage extraction 
recovery of the IS was 61.65%. We did not detect any 
apparent matrix effect in the determination of amitriptyline 
by this method of analysis. The values for the three quality 
control samples, i.e., LQC, MQC, and HQC were reported 
to be 100.4, 100.13, and 100.29%, respectively.
Carryover test
The HPLC chromatograms obtained by using the 
presently developed method of a blank sample (IS without 
amitriptyline) were analyzed following six consecutive 
analyses of ULOQ samples. The analysis revealed no 
obvious carryover.
Pharmacokinetic analysis
The pharmacokinetic parameters of amitriptyline 
are summarized in Table III .  The mean plasma 
concentrations versus time profiles of amitriptyline 
after oral administration with and without B. monnieri 
were characterized in rats and are presented in Figure 2. 
The peak plasma concentration (Cmax) was significantly 
(p< 0 .05)  increased  by  16 .8% (2 .86  ±  0 .11  to 
3.34 ± 0.06 µg/mL) in the presence of B. monnieri. 
Similarly, the area under the plasma concentration–time 
curve, AUC0–24 and AUC0-inf significantly increased by 
26.5% (29.34 ± 0.90 to 37.12 ± 0.62 µg·h/mL) and 36.7% 
TABLE I - Inter- and intra-day precision and recovery as accuracy of quality control samples (mean ± SD, n = 3)
Parameters Values
Inter-day (µg/mL) Intra-day (µg/mL)
LLOQ (10) MQC (30) ULOQ (50) LLOQ (10) MQC (30) ULOQ (50)
Precision
Mean ± SD 9.73 ± 0.03 28.96 ± 0.14 48.92 ± 0.98 9.65 ± 0.02 29.02 ± 0.16 49.06 ± 0.97
%RSD 1.65 2.98 1.85 1.52 0.85 1.45
Mean ± SD 9.95 ± 0.08 29.96 ± 0.04 49.82 ± 0.32 10.34 ± 0.02 30.02 ± 0.15 50.51 ± 0.25
Recovery
% Recovery 98.31 99.23 99.02 100.49 100.13 100.29
%RSD 0.85 0.15 0.54 0.99 0.51 0.185
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(38.38 ± 1.23 to 52.46 ± 1.73), respectively, compared 
to the control group. However, there was no significant 
change in the time to reach the peak plasma concentration 
(Tmax) of amitriptyline in the presence of B. monnieri. On 
the other hand, the calculated total oral clearance (CL) 
decreased by 26.2% (0.65 ± 0.02 to 0.48 ± 0.02 mL/h; 
p<0.05), while the estimated apparent oral volume of 
distribution (Vss) at steady state decreased by about 
15.5% (9.05 ± 0.26 to 7.65 ± 0.07 L/kg; p<0.05). Also, an 
increase of elimination half-life (t1/2) from 9.63 ± 0.21 to 
11.12 ± 0.39 h, which is about 15.5% as compared to the 
control group, was reported.
Our study revealed the potential of B. monnieri 
to significantly alter the oral pharmacokinetic profile of 
amitriptyline compared with the control. This is attributed 
to the considerable enhancement in the oral bioavailability 
of amitriptyline in rats. Various studies indicate the 
importance of herbal drugs to alter the expression of drug-
metabolizing enzymes and membrane transporters after 
administration. Cytochrome P450 (CYPs) are the primary 
TABLE II - Results of stability study of QC samples at different conditions (mean ± SD, n = 3)
Stability test Initial concentration ± SD (µg/mL)
Measured concentration ± SD 
(µg/mL)
Stock solution (4 °C for 3 months) 250.00 249.06 ± 1.26 
Working solution (4 °C for 3 months) 30.00 (HQC sample) 29.56 ± 0.56
Post-extraction (10 °C for 24 h)
a58.83 ± 0.12 58.60 ± 0.49
b29.25 ± 0.05 28.81 ± 0.45
c9.15 ± 0.09 9.04 ± 0.16
Freeze-thaw (from -20 °C to 25 °C, 3 cycles)
a59.01 ± 1.08 58.83 ± 0.42
b29.25 ± 1.12 29.11 ± 0.15
c9.88 ± 1.01 9.33 ± 0.43
Long term (-80 °C for 90 days)
a58.54 ± 0.98 58.82 ± 0.27
b29.42 ± 0.78 29.04 ± 0.22
c9.02 ± 0.29 8.94 ± 0.089
Note: avalues of ULOQ (60 µg/mL) and bvalues of MQC (30 µg/mL) samples and cvalues of LLOQ (10 µg/mL)
TABLE III - Pharmacokinetic parameters of amitriptyline control (alone) and co-administered with B.monnieri (mean ± SD, n = 6)
Pharmacokinetic parameters Amitriptyline only (mean ± SD, n =6)
Amitriptyline with B.monnieri 
(mean ± SD, n =6)
1Cmax (µg/mL) 2.86 ± 0.11 3.34 ± 0.06*
2Tmax (h) 4.0 ± 0.00 4.0 ± 0.00
3Kel (h−1) 0.07 ± 0.0079 0.062 ± 0.0021*
4AUC0-24(µg·h/mL) 29.34 ± 0.90 37.12 ± 0.62*
5AUC 0-inf (µg·h/mL) 38.38 ± 1.23 52.46 ± 1.73*
6AUMC0-inf (µg·h/mL) 617.77 ± 26.04 984.13 ± 63.33*
7t1/2 (h) 9.63 ± 0.21 11.13 ± 0.39*
8Vss (L/Kg) 9.05 ± 0.26 7.65 ± 0.07*
9CL (mL/h) 0.65 ± 0.02 0.48 ± 0.02*
10MRT (h) 16.09 ±0.27 18.74 ± 0.59*
*Significant difference from “ Amitriptyline alone” group with t-test,*P ≤ 0.05, 1 maximum blood concentration (Cmax) , 2 time of 
peak concentration(Tmax), 3elimination rate constant (kel ), 4 area under the concentration time profile curve until last observation 
(AUC0-24), 5 area under the concentration time profile curve from time 0 to infinity (AUC0-inf), 6 area under the first moment curve 
concentration time profile curve from time 0 to infinity (AUMC0-inf) , 7 half-life (t1/2), 8 Steady‐State Volume distribution (Vss),9 Total 
clearance (CL), and 10 mean residence time (MRT)
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enzymes in the liver involved in the hepatic metabolism 
of most drugs. These comprise CYP1A2, CYP3A4, 
CYP2C9, CYP2C19, CYP2D6, and CYP2E1 (Badyal, 
Dadhich, 2001). Amitriptyline, after oral administration, 
is readily absorbed by the gastrointestinal tract, followed 
by its metabolism, majorly on its first pass through the 
liver. CYP2D6-, CYP3A4-, and CYP2C19-mediated 
N-demethylation into nortriptyline constitute the main 
pathway for its metabolism (Rudorfer, Potter, 1999). 
Recently, a study conducted to evaluate the effects of a 
standardized extract of B. monnieri on the expression and 
activity of hepatic and intestinal cytochrome P450 3A and 
P-glycoprotein (Pgp) in rats revealed that administration 
of B. monnieri for 7 days modulated the expression of 
CYP3A and Pgp. Administration of B. monnieri led to a 
reduced expression of CYP3A and concomitant decrease 
in the CYP3A-dependent testosterone hydroxylase 
catalytic activity in liver and intestine (Singh et al., 2013). 
Another study reported similar findings that B. monnieri 
moderately inhibited CYP2C19, CYP2C9, CYP1A2, and 
CYP3A4 but weakly inhibited CYP2D6 (Ramasamy, 
Kiew, Chung, 2014). These findings indicated toward 
the possible potential of B. monnieri to contribute to 
herb–drug interactions when orally co-administered with 
drugs metabolized by CYP1A2, CYP3A4, CYP2C9, and 
CYP2C19. Based on this hypothesis, the plasma levels 
of drug administered concomitantly could be elevated by 
inhibition of drug-metabolizing enzymes to prolong the 
pharmacological effects of the drug, thereby increasing 
the incidence of drug-induced toxicity (Hu et al., 2005). 
The enhanced bioavailability of amitriptyline observed in 
the current study might result from the inhibition of the 
metabolizing enzymes, CYP3A4 and CYP2C19, in the 
intestinal mucosa or liver by B. monnieri. Another reason 
for the inhibition of the CYP enzymes by B. monnieri 
could be the presence of other constituents in the extract, 
such as free aglycones, such as jujubogenin (Kawai et al., 
1974) and pseudojujubogenin (Kawai, Shibata, 1978), 
which are more lipophilic. The better lipophilic property 
of free aglycones enhances their binding to the CYP 
isoforms through hydrogen bonding, thereby resulting 
in stronger inhibitory effects (Ramasamy, Kiew, Chung, 
2014). The increase in Cmax and area under curve (AUC) 
and decrease in oral clearance may lead to increase in 
the total bioavailability of amitriptyline, leading to toxic 
effects. Hence, concomitant administration of B. monnieri 
preparations with drugs that are primarily cleared through 
CYP2C19-, CYP2C9-, CYP1A2-, and CYP3A4-mediated 
metabolism should be administered to the patients with 
increased vigilance .
CONCLUSION
The findings of the present study suggest that the 
medicinal herb, B. monnieri exhibit significant potential 
to alter pharmacokinetics of amitriptyline in rats. The 
herb–drug interaction was reflected by the B. monnieri-
mediated increased intestinal absorption and reduced 
first-pass metabolism of amitriptyline in the intestine and 
liver through inhibition of CYP2C and CYP3A enzymes. 
The results obtained in the present study indicate toward 
exercising caution while administering a combination of 
FIGURE 2 - Plasma concentration-time curve of amitriptyline (25 mg/kg, p.o) administered with and without B.monnieri 
(31 mg/kg/day, p.o) in rats (each data is mean ± SD, n = 6)
Effect of herb-drug interactions of Bacopa monnieri Linn. (Brahmi) formulation on the pharmacokinetics of amitriptyline in rats
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B. monnieri and amitriptyline. Consequently, concomitant 
use of B. monnieri and amitriptyline warrants close 
monitoring for possible drug interactions. Further 
confirmation of these results in humans would assist in 
evaluating the clinical consequences of such interactions.
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